KARE Biosciences focuses on developing innovative therapies for neurodegenerative diseases, leveraging advanced technologies to create targeted treatments. Their pipeline includes a range of product candidates designed to address conditions such as Alzheimer's and Parkinson's disease. The company employs a unique approach that combines insights from neuroscience with cutting-edge drug development techniques, aiming to enhance the efficacy and safety of their therapeutic offerings.

The technologies utilized by KARE Biosciences encompass a variety of methodologies, including small molecule drug discovery and advanced screening processes. They emphasize the importance of understanding the underlying biological mechanisms of neurodegeneration, which informs their drug design and development strategies. By integrating data-driven insights and state-of-the-art research techniques, KARE Biosciences is committed to advancing the treatment landscape for patients suffering from debilitating neurological disorders.

United States

KARE Biosciences is a biotechnology company looking to license products and partner with other companies to develop drugs for a wide range of indications. KARE Biosciences is currently focused on repurposing ramatroban for the treatment of acute COVID-19 and long COVID. Ramatroban has great potential in many other indications including sickle cell disease, cardiovascular disease, rhabdomyolysis induced acute kidney injury, community acquired pneumonia, dengue fever, pulmonary fibrosis, Alzheimer's disease and more. Please visit our website for more information about our products.

KARE Biosciences

Company Details